SCHEMBL1351864

SCHEMBL1351864

Clc1ccc(CN2Cc3ccccc3N3CCN(Cc4ccccc4)CC3C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 2/20 0.54
▸ DRD2 P14416 7/20 0.50
▸ BCHE P06276 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ BACE1 P56817 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ DRD4 P21917 9/20 0.45
▸ TACR1 P25103 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ ADRA1D P25100 2/20 0.43
▸ ADRA1A P35348 2/20 0.43
▸ ADRA1B P35368 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1351856 0.94 DRD2 (0.55) SIGMAR1DRD2ACHEALDH1A1TACR1
SCHEMBL1351067 0.89 SIGMAR1 (0.57) SIGMAR1DRD2ALDH1A1DRD4
SCHEMBL1351573 0.89 LMNA (0.55) DRD2BCHEACHEBACE1ALDH1A1
SCHEMBL1348893 0.89 DRD2 (0.49) SIGMAR1DRD2BCHEACHEBACE1
SCHEMBL1350774 0.89 DRD2 (0.49) DRD2BCHEACHEBACE1DRD4
SCHEMBL1351299 0.89 DRD2 (0.49) SIGMAR1DRD2DRD4
SCHEMBL1349520 0.89 DRD2 (0.49) SIGMAR1DRD2BCHEACHEBACE1
SCHEMBL1351983 0.88 DRD2 (0.47) SIGMAR1DRD2ALDH1A1DRD4
SCHEMBL1350537 0.87 SIGMAR1 (0.57) SIGMAR1DRD2ALDH1A1DRD4CYP1A2
SCHEMBL1352490 0.86 DRD2 (0.49) SIGMAR1DRD2ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160052929-A1 BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES ABBVIE INC. 2016-02-25 — — US claimed
US-20140163014-A1 BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES ABBVIE INC. 2014-06-12 — — US claimed
US-8673896-B2 Benzodiazepine and pyridodiazepine derivatives ABBVIE INC. (US) 2014-03-18 — — US claimed
US-20110288069-A1 Benzodiazepine and Pyridodiazepine Derivatives ABBOTT LABORATORIES (US) 2011-11-24 — — US claimed
US-20160052929-A1 BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES ABBVIE INC. 2016-02-25 — — US disclosed
US-9133206-B2 Benzodiazepine and pyridodiazepine derivatives ABBVIE INC. (US) 2015-09-15 — — US disclosed
US-20140163014-A1 BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES ABBVIE INC. 2014-06-12 — — US disclosed
US-8673896-B2 Benzodiazepine and pyridodiazepine derivatives ABBVIE INC. (US) 2014-03-18 — — US disclosed
US-20110288069-A1 Benzodiazepine and Pyridodiazepine Derivatives ABBOTT LABORATORIES (US) 2011-11-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288069-A1 Benzodiazepine and Pyridodiazepine Derivatives GABRA3, GABRB3, GABRA1 SIGMAR1 149/4885DRD2 56/4885BCHE 1172/4885
US-20160052929-A1 BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES GABRA3, GABRB3, GABRA1 SIGMAR1 149/4885DRD2 56/4885BCHE 1172/4885
US-20140163014-A1 BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES GABRA3, GABRB3, GABRA1 SIGMAR1 149/4885DRD2 56/4885BCHE 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback